Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01473251 · ClinicalTrials.gov registry record · NA
Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration
A NA study, sponsored by Vitreo-Retinal Associates, Michigan.
- Completed
- Registry status
- NA
- Development phase
- 16
- Enrollment target
NCT01473251: Completed NA study, sponsored by Vitreo-Retinal Associates, Michigan.
NCT01473251 is a NA study that has completed, run by Vitreo-Retinal Associates, Michigan. The registered enrollment target is 16 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01473251, a NA study, has completed, sponsored by Vitreo-Retinal Associates, Michigan.
- COMPLETED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to measure biomarkers in the vitreous of patients undergoing Lucentis or avastin treatment.
Primary Outcome
Analysis of collected vitreous samples in regards to identification of biomarkers that are prognostic for response to anti-angiogenic treatment of retinopathy, and the exploration of a more effective dosing regiment for intravitreal injections of Lucentis/Avastin for exudative macular degeneration and Avastin for diabetic macular edema.
Interventions
- DRUG Avastin
- DRUG Lucentis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2011-11 |
| Est. Completion | 2014-04 |
| Phase | NA |
What the finished NCT01473251 record still lists
NCT01473251 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Avastin is the first listed.
NCT01473251 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01473251 about?
NCT01473251 is a clinical study titled "Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration". The purpose of this study is to measure biomarkers in the vitreous of patients undergoing Lucentis or avastin treatment.
What is the current status of trial NCT01473251?
This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2011-11. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01473251?
The interventions under investigation include: Avastin (DRUG), Lucentis (DRUG).
Who is sponsoring clinical trial NCT01473251?
This trial is sponsored by Vitreo-Retinal Associates, Michigan, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01473251's enrollment target sits among peer trials
16 1871st of 2000 higher than 120 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia